Literature DB >> 10029072

Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol.

M Hardwick1, D Fertikh, M Culty, H Li, B Vidic, V Papadopoulos.   

Abstract

Aberrant cell proliferation and increased invasive and metastatic behavior are hallmarks of the advancement of breast cancer. Numerous studies implicate a role for cholesterol in the mechanisms underlying cell proliferation and cancer progression. The peripheral-type benzodiazepine receptor (PBR) is an Mr 18,000 protein primarily localized to the mitochondria. PBR mediates cholesterol transport across the mitochondrial membranes in steroidogenic cells. A role for PBR in the regulation of tumor cell proliferation has also been shown. In this study, we examined the expression, characteristics, localization, and function of PBR in a battery of human breast cancer cell lines differing in their invasive and chemotactic potential as well as in several human tissue biopsies. Expression of PBR ligand binding and mRNA was dramatically increased in the highly aggressive cell lines, such as MDA-231, relative to nonaggressive cell lines, such as MCF-7. PBR was also found to be expressed at high levels in aggressive metastatic human breast tumor biopsies compared with normal breast tissues. Subcellular localization with both antibodies and a fluorescent PBR drug ligand revealed that PBR from the MDA-231 cell line as well as from aggressive metastatic human breast tumor biopsies localized primarily in and around the nucleus. This localization is in direct contrast to the largely cytoplasmic localization seen in MCF-7 cells, normal breast tissue, and to the typical mitochondrial localization seen in mouse tumor Leydig cells. Pharmacological characterization of the receptor and partial nucleotide sequencing of PBR cDNA revealed that the MDA-231 PBR is similar, although not identical, to previously described PBR. Addition of high affinity PBR drug ligands to MDA-231 cells increased the incorporation of bromodeoxyuridine into the cells in a dose-dependent manner, suggesting a role for PBR in the regulation of MDA-231 cell proliferation. Cholesterol uptake into isolated MDA-231 nuclei was found to be 30% greater than into MCF-7 nuclei. High-affinity PBR drug ligands regulated the levels of cholesterol present in MDA-231 nuclei but not in MCF-7. In addition, the PBR-dependent MDA-231 cell proliferation was found to highly correlate (r = -0.99) with the PBR-mediated changes in nuclear membrane cholesterol levels. In conclusion, these data suggest that PBR expression, nuclear localization, and PBR-mediated cholesterol transport into the nucleus are involved in human breast cancer cell proliferation and aggressive phenotype expression, thus participating in the advancement of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

Review 1.  The peripheral benzodiazepine receptors: a review.

Authors:  A Beurdeley-Thomas; L Miccoli; S Oudard; B Dutrillaux; M F Poupon
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 2.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

3.  Functional characterization of the human translocator protein (18kDa) gene promoter in human breast cancer cell lines.

Authors:  Amani Batarseh; Keith D Barlow; Daniel B Martinez-Arguelles; Vassilios Papadopoulos
Journal:  Biochim Biophys Acta       Date:  2011-09-18

4.  The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; Andrew Bauer; Aneeta Patel; John Costello; Kenneth D Burman; Leonard Wartofsky; Matthew J Hardwick; Vasyl V Vasko
Journal:  J Endocrinol       Date:  2012-05-29       Impact factor: 4.286

5.  PKA-mediated phosphorylation of Dexras1 suppresses iron trafficking by inhibiting S-nitrosylation.

Authors:  Yong Chen; Lauren Mathias; Juliana M Falero-Perez; Sangwon F Kim
Journal:  FEBS Lett       Date:  2015-09-07       Impact factor: 4.124

6.  Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer.

Authors:  Shelby K Wyatt; H Charles Manning; Mingfeng Bai; Stephanie N Bailey; Pascal Gallant; Guobin Ma; Laura McIntosh; Darryl J Bornhop
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

7.  The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway.

Authors:  Tao Zhou; Ying Dang; Yong-Hui Zheng
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

8.  Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism.

Authors:  Fei Li; Jian Liu; Yi Zheng; R Michael Garavito; Shelagh Ferguson-Miller
Journal:  Science       Date:  2015-01-30       Impact factor: 47.728

9.  Translocator protein blockade reduces prostate tumor growth.

Authors:  Arlee Fafalios; Ardavan Akhavan; Anil V Parwani; Robert R Bies; Kevin J McHugh; Beth R Pflug
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

10.  Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.

Authors:  Paula M Maloberti; Alejandra B Duarte; Ulises D Orlando; María E Pasqualini; Angela R Solano; Carlos López-Otín; Ernesto J Podestá
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.